As part of our ongoing series on new registrations in Australia, we have added a product review of the use of Macitentan as monotherapy or in combination with a phosphodiesterase type 5 inhibitor in patients with pulmonary arterial hypertension.
This review discusses importance of risk assessment, current treatment of PAH, Macitentan pharmacological properties, dosage and administration, and efficacy and tolerability as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Associate Professor Eugene Kotlyar, Senior Staff Cardiologist in Heart Failure, Cardiac transplantation and Pulmonary hypertension at St Vincent’s Hospital, Sydney.
Please login below to download this issue (PDF)